Wenchao Zhou, Yaqin Hu, Yun Qiu, Hao Zheng, Juan Jiang, Jiangyi Luo, Juanjiang Wu, Hanwen Yuan, Xudong Zhou, Liming Gong, Yixing Qiu, Wei Wang
{"title":"沙参麦冬汤对慢性支气管炎的影响:多方法观察。","authors":"Wenchao Zhou, Yaqin Hu, Yun Qiu, Hao Zheng, Juan Jiang, Jiangyi Luo, Juanjiang Wu, Hanwen Yuan, Xudong Zhou, Liming Gong, Yixing Qiu, Wei Wang","doi":"10.2174/0113816128363449250526092829","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Shashen Maidong Decoction (SSMDD) is a traditional Chinese medicine (TCM) formula used for treating chronic bronchitis (CB).</p><p><strong>Objectives: </strong>This study aims to explore the mechanism of SSMDD against CB, focusing on its active components and their impact on Interleukin 6 (IL-6), a key inflammatory factor.</p><p><strong>Materials and methods: </strong>Network pharmacology, a method that helps identify potential active components and their interactions in a biological network, was used to predict SSMDD's effects. Molecular docking, a computational approach for predicting the binding affinity between small molecules and target proteins, was utilized to elucidate the mechanisms of action. Transcriptomic analysis, ELISA, and western blot assays were subsequently implemented for mechanism validation.</p><p><strong>Results: </strong>Network pharmacology analysis identified quercetin and kaempferol as key active components of SSMDD, with a high affinity for IL-6. Transcriptomic data confirmed the regulation of inflammation-related pathways by SSMDD, aligning with the predicted targets. In the ELISA determination, compared with the model group, the IL-6 levels in the samples treated with quercetin and kaempferol were reduced by 55% and 36%, respectively. The western blot results showed that the expression of IL-6 protein in these samples decreased by 33% and 25%, respectively.</p><p><strong>Conclusion: </strong>SSMDD exhibits anti-inflammatory activity against CB by targeting IL-6. This study provides a deeper understanding of the mechanisms through which SSMDD exerts its therapeutic effects on CB. Moreover, these findings also suggest that SSMDD may offer insights for future treatments of other inflammatory diseases, potentially improving patient outcomes and developing novel therapeutic strategies. Future studies should explore the effects of additional targets and active compounds within SSMDD and evaluate its broader applications in inflammatory conditions.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Shashen Maidong Decoction's Effects on Chronic Bronchitis: A Multi-Method Approach.\",\"authors\":\"Wenchao Zhou, Yaqin Hu, Yun Qiu, Hao Zheng, Juan Jiang, Jiangyi Luo, Juanjiang Wu, Hanwen Yuan, Xudong Zhou, Liming Gong, Yixing Qiu, Wei Wang\",\"doi\":\"10.2174/0113816128363449250526092829\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Shashen Maidong Decoction (SSMDD) is a traditional Chinese medicine (TCM) formula used for treating chronic bronchitis (CB).</p><p><strong>Objectives: </strong>This study aims to explore the mechanism of SSMDD against CB, focusing on its active components and their impact on Interleukin 6 (IL-6), a key inflammatory factor.</p><p><strong>Materials and methods: </strong>Network pharmacology, a method that helps identify potential active components and their interactions in a biological network, was used to predict SSMDD's effects. Molecular docking, a computational approach for predicting the binding affinity between small molecules and target proteins, was utilized to elucidate the mechanisms of action. Transcriptomic analysis, ELISA, and western blot assays were subsequently implemented for mechanism validation.</p><p><strong>Results: </strong>Network pharmacology analysis identified quercetin and kaempferol as key active components of SSMDD, with a high affinity for IL-6. Transcriptomic data confirmed the regulation of inflammation-related pathways by SSMDD, aligning with the predicted targets. In the ELISA determination, compared with the model group, the IL-6 levels in the samples treated with quercetin and kaempferol were reduced by 55% and 36%, respectively. The western blot results showed that the expression of IL-6 protein in these samples decreased by 33% and 25%, respectively.</p><p><strong>Conclusion: </strong>SSMDD exhibits anti-inflammatory activity against CB by targeting IL-6. This study provides a deeper understanding of the mechanisms through which SSMDD exerts its therapeutic effects on CB. Moreover, these findings also suggest that SSMDD may offer insights for future treatments of other inflammatory diseases, potentially improving patient outcomes and developing novel therapeutic strategies. Future studies should explore the effects of additional targets and active compounds within SSMDD and evaluate its broader applications in inflammatory conditions.</p>\",\"PeriodicalId\":10845,\"journal\":{\"name\":\"Current pharmaceutical design\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current pharmaceutical design\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0113816128363449250526092829\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128363449250526092829","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Shashen Maidong Decoction's Effects on Chronic Bronchitis: A Multi-Method Approach.
Background: Shashen Maidong Decoction (SSMDD) is a traditional Chinese medicine (TCM) formula used for treating chronic bronchitis (CB).
Objectives: This study aims to explore the mechanism of SSMDD against CB, focusing on its active components and their impact on Interleukin 6 (IL-6), a key inflammatory factor.
Materials and methods: Network pharmacology, a method that helps identify potential active components and their interactions in a biological network, was used to predict SSMDD's effects. Molecular docking, a computational approach for predicting the binding affinity between small molecules and target proteins, was utilized to elucidate the mechanisms of action. Transcriptomic analysis, ELISA, and western blot assays were subsequently implemented for mechanism validation.
Results: Network pharmacology analysis identified quercetin and kaempferol as key active components of SSMDD, with a high affinity for IL-6. Transcriptomic data confirmed the regulation of inflammation-related pathways by SSMDD, aligning with the predicted targets. In the ELISA determination, compared with the model group, the IL-6 levels in the samples treated with quercetin and kaempferol were reduced by 55% and 36%, respectively. The western blot results showed that the expression of IL-6 protein in these samples decreased by 33% and 25%, respectively.
Conclusion: SSMDD exhibits anti-inflammatory activity against CB by targeting IL-6. This study provides a deeper understanding of the mechanisms through which SSMDD exerts its therapeutic effects on CB. Moreover, these findings also suggest that SSMDD may offer insights for future treatments of other inflammatory diseases, potentially improving patient outcomes and developing novel therapeutic strategies. Future studies should explore the effects of additional targets and active compounds within SSMDD and evaluate its broader applications in inflammatory conditions.
期刊介绍:
Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.
Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.